• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Kineta Inc. (Amendment)

    5/2/24 4:39:36 PM ET
    $KA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KA alert in real time by email
    SC 13D/A 1 ka_-_bartoszek_13da_2024.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    Schedule 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    ________________________

    KINETA, INC.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    49461C 102

    (CUSIP Number)

    Craig W. Philips

    President

    Kineta, Inc.

    7683 SE 27th Street, Suite 481

    Mercer Island, WA 98040

    (206) 378-0400

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    May 1, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. 

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    SCHEDULE 13D

    CUSIP No. 49461C 102

    1.

    Name of Reporting Person

     

    RLB Holdings Connecticut, LLC

    2.

    Check the Appropriate Box if a Member of a Group

     

    (a) □

    (b) □

    3.

    SEC Use Only

    4.

    Source of Funds (See Instructions)

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    ☐

     

    Not Applicable

    6.

    Citizenship or Place of Organization

     

    Connecticut

    Number of Shares Beneficially Owned by Each Reporting Person With

    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    1,782,873*

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    1,782,873*

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,782,873

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

    □

    13.

    Percent of Class Represented by Amount in Row (11)

     

    15.7%**

    14.

    Type of Reporting Person

     

    OO

    *Includes warrants to purchase an aggregate of 34,400 shares of the Issuer’s common stock, par value $0.001 per share (“Common Stock”) that are exercisable within 60 days of April 25, 2024. Raymond Bartoszek is a Managing Member of RLB Holdings Connecticut, LLC (“RLB”) and shares voting and investment power with respect to these shares.

    **Percentage ownership is based on 11,350,460 shares of Common Stock of the Issuer outstanding as of April 25, 2024, as reported in the Issuer’s Definitive Proxy Statement on Schedule 14A (File No. 001-37695) filed with the Securities and Exchange Commission (the “Commission”) on April 26, 2024 (the “Proxy Statement”).

     

     


     

    CUSIP No. 49461C 102

    1.

    Name of Reporting Person

     

    Raymond Bartoszek

    2.

    Check the Appropriate Box if a Member of a Group

     

    (a) □

    (b) □

    3.

    SEC Use Only

    4.

    Source of Funds (See Instructions)

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    ☐

     

    Not Applicable

    6.

    Citizenship or Place of Organization

     

    U.S.A.

    Number of Shares Beneficially Owned by Each Reporting Person With

    7.

    Sole Voting Power

     

    51,659*

    8.

    Shared Voting Power

     

    1,782,873**

    9.

    Sole Dispositive Power

     

    51,659*

    10.

    Shared Dispositive Power

     

    1,782,873**

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,834,532

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

    □

    13.

    Percent of Class Represented by Amount in Row (11)

     

    16.2%***

    14.

    Type of Reporting Person

     

    IN

    *Includes (i) an aggregate of 2,001 shares of Common Stock held by the Reporting Person’s minor children, and (ii) 32,452 shares of Common Stock underlying stock options held by the Reporting Person that are exercisable within 60 days of April 25, 2024.

    **Includes (i) 1,748,873 shares held of record by RLB, and (iii) warrants to purchase an aggregate of 34,400 shares of Common Stock held by RLB that are exercisable within 60 days of April 25, 2024. The Reporting Person is a Managing Member of RLB and shares voting and investment power with respect to these shares.

    ***Percentage ownership is based on 11,350,460 shares of Common Stock of the Issuer outstanding as of April 25, 2024, as reported in the Proxy Statement.

     

     


     

    SCHEDULE 13D

    This Amendment No. 1 (“Amendment No. 1”) amends and supplements the Schedule 13D filed by RLB and Raymond Bartoszek (together, the “Reporting Persons”) with the Commission on February 14, 2023 (the “Original Schedule 13D” and, together with Amendment No. 1, the “Schedule 13D”). The Original Schedule 13D remains in full force and effect, except as specifically amended by this Amendment No. 1. Capitalized terms used but not defined herein shall have the meaning set forth in the Original Schedule 13D.

    Item 3. Source and Amount of Funds

    An aggregate of 903,995 shares of Common Stock (the “Settlement Shares”) to which this Amendment No. 1 relates were acquired by RLB pursuant to a settlement agreement and mutual release, dated April 22, 2024 (the “Settlement Agreement”), by and between the Issuer and RLB to continue RLB’s investment in the Issuer and to resolve any and all potential claims or causes of action in connection with RLB’s failure to purchase $2,500,000 shares of Common Stock, pursuant to a financing agreement, dated as of June 5, 2022, as amended on October 24, 2022, December 5, 2022, March 29, 2023, May 1, 2023, July 21, 2023 and October 13, 2023.

    Pursuant to the Settlement Agreement, on April 23, 2024, RLB purchased $500,000 of shares of Common Stock, adjusted as necessary to avoid the issuance of any fractional shares (the “Share Purchase Price”), and in exchange, on May 1, 2024, the Issuer issued to RLB 903,995 shares, which is equal to the Share Purchase Price divided by the sum of (i) the Nasdaq Official Closing Price of Common Stock for the five trading days prior to the date of the Agreement (the “NOCP”) and (ii) 20% of the NOCP.

    Item 4. Purpose of the Transaction

    The Reporting Persons acquired the Settlement Shares pursuant to the Settlement Agreement. The information contained in Item 3 of this Amendment No. 1 is incorporated herein by reference.

    Item 5. Interest in Securities of the Issuer

    (a) The aggregate percentage of Common Stock that the Reporting Persons may be deemed to beneficially own is determined in accordance with the rules of the SEC and is based on 11,350,460 shares of Common Stock of the Issuer issued and outstanding as reported in the Proxy Statement. Based on the foregoing, the Reporting Persons may be deemed to beneficially own 16.2% of the Issuer’s Common Stock in the aggregate.

    As of the date of this Amendment No. 1, the Reporting Persons beneficially owned, in the aggregate, 1,834,532 shares of Common Stock.

    Each of the Reporting Persons, as a result of the relationships described in Item 2, may be deemed to directly or indirectly beneficially own the shares of Common Stock reported on the cover pages to this Schedule 13D for each such Reporting Person. See also Items 11 and 13 of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and the percentage of shares of Common Stock beneficially owned by each of the Reporting Persons.

     


     

    (b) Number of shares to which RLB has:

    Sole power to vote or to direct the vote: 0

    Shared power to vote or to direct the vote: 1,748,473

    Sole power to dispose or to direct the disposition of: 0

    Shared power to vote or to direct the disposition of: 1,748,473

     

    Number of shares to which Raymond Bartoszek has:

    Sole power to vote or to direct the vote: 51,659

    Shared power to vote or to direct the vote: 1,782,873

    Sole power to dispose or to direct the disposition of: 51,659

    Shared power to vote or to direct the disposition of: 1,782,873

     

    (c) Except as otherwise described in this Schedule 13D, the Reporting Persons have not effected any transaction related to the Common Stock during the past 60 days other than the Settlement Shares described in Item 3.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    The information contained in Item 3 of this Amendment No. 1 is incorporated herein by reference.

    Item 7. Material to be Filed as Exhibits.

    Exhibit No.

    Name

    1.

    Settlement Agreement and Mutual Release, dated as of April 22, 2024, by and between the Issuer and RLB (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on April 24, 2024).

     

     

     


     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

    Date: May 2, 2024

    RLB HOLDINGS CONNECTICUT, LLC

     

    By: /s/ Raymond Bartoszek Name: Raymond Bartoszek

    Title: Managing Member

     

     

    RAYMOND BARTOSZEK

     

    /s/ Raymond Bartoszek

    Name: Raymond Bartoszek

     


    Get the next $KA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Kineta Inc. (Amendment)

      SC 13D/A - KINETA, INC./DE (0001445283) (Subject)

      5/2/24 4:39:36 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

      Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The company will present additional scientific data in 2024 at an upcoming scientific meeting. SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has completed the enrollment of new patients into the monotherapy arm of the VI

      10/8/24 9:00:00 AM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

      SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, has announced that on November 8, 2024 Jason Henry M.D., Associate Director, Drug Development at Sarah Cannon Research Institute, Denver Colorado will be presenting the poster wi

      10/4/24 9:05:00 AM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1

      TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer SEATTLE, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that TuHURA Biosciences Inc (TuHURA) is exercising its right to extend their exclusivity and right of first offer agreement (the "Agreement") for Kineta's VISTA blocking antibody KVA12123. Under the terms of the A

      10/2/24 4:05:00 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KA
    SEC Filings

    See more
    • Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - KINETA, INC./DE (0001445283) (Filer)

      10/2/24 4:07:07 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - KINETA, INC./DE (0001445283) (Filer)

      9/19/24 9:53:51 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kineta Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - KINETA, INC./DE (0001445283) (Filer)

      9/19/24 9:21:01 AM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Foote Marion R

      4 - KINETA, INC./DE (0001445283) (Issuer)

      9/5/24 4:20:49 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Iadonato Shawn

      4 - KINETA, INC./DE (0001445283) (Issuer)

      9/5/24 4:21:14 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Peters Richard

      4 - KINETA, INC./DE (0001445283) (Issuer)

      9/5/24 4:21:48 PM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KA
    Leadership Updates

    Live Leadership Updates

    See more
    • Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board

      SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the appointment of Myriam Chalabi, M.D. and Evan Ya-Wen Yu, M.D. to the company's immuno-oncology focused Scientific Advisory Board (SAB). Dr. Chalabi and Dr. Yu will join Kineta's SAB that includes Lisa Coussens, Ph.D., Michael Curran, Ph.D. and Patricia LoRusso, D.O. to guide the clinical development of KVA12123, the company's VISTA blocking immunotherapy. "We are delighted to have Dr. Chalabi and Dr. Yu join Kineta's Scientific Advisory Board," stated Thierry Guillaudeux, P

      3/1/23 6:30:00 AM ET
      $KA
      Biotechnology: Pharmaceutical Preparations
      Health Care